Articles Vol. 67 No. CĐ11-NCKH 31/07/2026

ANTI-GAD AND C-PEPTIDE IN EARLY-ONSET NON-OVERWEIGHT PATIENTS WITH TYPE 2 DIABETES: IMPLICATIONS FOR LADA SCREENING

Dang Dang Khoa1,2, Ngo Van Truyen1,2, Huynh Van Tan1,2, Nguyen Bao Toan3,4
1 Can Tho University of Medicine and Pharmacy
2 Trường Đại học Y Dược Cần Thơ
3 Hoa Hao Medical Company Limited
4 Công ty Trách nhiệm Hữu hạn Y tế Hòa Hảo
DOI: 10.52163/yhc.v67iCD11.6038
29 Views
0 Downloads
Abstract

Objective: To determine the prevalence of anti-GAD positivity, fasting C-peptide levels, and associated factors in order to suggest screening for latent autoimmune diabetes in adults (LADA).

Methods: A cross-sectional descriptive study was conducted on 76 patients with diabetes mellitus. Serum anti-GAD antibodies, fasting C-peptide, blood glucose, HbA1c, and lipid profiles were measured. Comparisons between groups were performed using Fisher’s exact test and the Mann–Whitney U test. Multivariable linear regression analysis was used to identify factors associated with fasting C-peptide levels.

Results: The prevalence of anti-GAD positivity was 5.3%, while 13.2% of patients had low fasting C-peptide levels. Patients with positive anti-GAD tended to have greater β-cell dysfunction compared to those with negative anti-GAD. The low C-peptide group had significantly higher fasting blood glucose and HbA1c levels than the normal/high C-peptide group (p < 0.05). The multivariable regression model was statistically significant (p = 0.007), showing that glucose and HDL-c were independently and inversely associated with fasting C-peptide levels.

Conclusion: β-cell dysfunction was closely associated with poor glycemic control in patients with early-onset diabetes. Autoimmune features may be present in a small subgroup of patients. Measurement of fasting C-peptide and anti-GAD may be useful for patient stratification and treatment orientation.

References
[1]
American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care, 2023, 46(1): S19-S40. https://doi.org/10.2337/dc23-S002. Google Scholar
[2]
Rajkumar V, Levine SN. Latent Autoimmune Diabetes. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2024. Available from link: https://www.ncbi.nlm.nih.gov/books/NBK557897/. Google Scholar
[3]
Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications. Nat Rev Endocrinol, 2017, 13(11): 674-686. doi: 10.1038/nrendo.2017.99. Google Scholar
[4]
Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab, 2017, 94(12): 4635-4644. doi: 10.1210/jc.2009-1120. Google Scholar
[5]
Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med, 2013, 30(7): 803-17. doi: 10.1111/dme.12159. Google Scholar
[6]
Guglielmi C, Palermo A, Pozzilli P. Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy. Diabetes Metab Res Rev, 2012, 28(2): 40-46. doi: 10.1002/dmrr.2345. Google Scholar
[7]
Hwangbo Y et al. Prevalence and clinical characteristics of recently diagnosed type 2 diabetes patients with positive anti-glutamic Acid decarboxylase antibody. Diabetes Metab J, 2012, 36(2): 136-43. doi: 10.4093/dmj.2012.36.2.136. Google Scholar
[8]
Fourlanos S, Dotta F, Greenbaum CJ, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia, 2005, 48: 2206-2212. https://doi.org/10.1007/s00125-005-1960-7. Google Scholar
[9]
Tam AA, Ozdemir D, Bestepe N, et al. Low rate of latent autoimmune diabetes in adults (LADA) in patients followed for type 2 diabetes: A single center's experience in Turkey. Arch Endocrinol Metab, 2021, 64(5): 584-590. doi: 10.20945/2359-3997000000268. Google Scholar
[10]
Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity, Trends Endocrinol Metab, 2010, 21(6): 345-52. doi: 10.1016/j.tem.2010.01.009. Google Scholar
[11]
Al-Zubairi T, Al-Habori M, Saif-Ali R. Latent Autoimmune Diabetes in Adults (LADA) and its Metabolic Characteristics among Yemeni Type 2 Diabetes; Mellitus Patients. Diabetes Metab Syndr Obes, 2021, 14: 4223-4232. doi: 10.2147/DMSO.S332416. Google Scholar
[12]
Guglielmi C, Palermo A, Pozzilli P. Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy. Diabetes Metab Res Rev, 2012, 28(2): 40-46. doi: 10.1002/dmrr.2345. Google Scholar